- IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, SeaportWith major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics. Celea has corralled $180 million to see ifEndpoints · 25d ago↗ source
- Roche KRAS drug succeeds in head-to-head lung cancer study<figure><div><img src="https://imgproxy.divecdn.com/Sx5xDgNmDFUjqj0qcGVTS7IkwSLxPHMSmgzypS8Uexg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xOTM3MjY1MDU5XzEua…BioPharma Dive · 25d ago↗ source
- STAT+: Roche drug sets new standard for KRAS-driven lung cancerBiotech's bull market, Vertex's gene therapy expansion, and more news from The ReadoutSTAT · 25d ago